Maze Therapeutics (MAZE) Share-based Compensation (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Share-based Compensation data on file, last reported at $58.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 1697.89% year-over-year to $58.0 million; the trailing twelve-month figure through Mar 2026 stood at $58.0 million (up 449.14% YoY), and the FY2025 full-year result was $28.4 million, down 5.33% from the prior year.
• Share-based Compensation climbed to $58.0 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $58.0 million in Q1 2026 to a low of $2.1 million in Q2 2024.
• A 3-year average of $12.3 million and a median of $3.2 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 39.65% in 2025 and jumped 1697.89% in 2026, its largest moves.
• Tracing MAZE's Share-based Compensation over 3 years: stood at $2.9 million in 2024, then jumped by 113.01% to $6.1 million in 2025, then soared by 855.05% to $58.0 million in 2026.
• Business Quant data shows MAZE's Share-based Compensation at $58.0 million in Q1 2026, $6.1 million in Q4 2025, and $30.6 million in Q3 2025.